Drugs / MK-1942
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04308304 | Feb 2021 → May 2022 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT05602727 | Dec 2022 → Sep 2023 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | Missed primary |
| Phase 2 | NCT04663321 | May 2021 → Sep 2023 | — | Merck Sharp & Dohme LLC | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1942 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04308304 ↗ |
| Action | Inhibit | “a negative allosteric modulator of mGluR2” PMID 41854661 ↗ Mar 2026 |
| Route | Oral | “taken twice daily (BID) by mouth” NCT04308304 ↗ |